Novartis India headquarters in Mumbai April 1, 2013. REUTERS/Vivek Prakash

Headlines have been trumpeting the Indian Supreme Court’s decision to deny a new patent for the cancer drug Gleevec as an attack on intellectual property rights and a win for patients in need of cheap drugs. Those headlines are misleading.